Cargando…

Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI Score

SIMPLE SUMMARY: The Lung Immune Prognostic Index (LIPI) is a score that combines pretreatment dNLR (neutrophils/(leukocytes − neutrophils) and lactate dehydrogenase (LDH) and is correlated with outcomes in patients with non-small-cell lung cancer treated with anti PD-(L)1 but has not been validated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pierro, Monica, Baldini, Capucine, Auclin, Edouard, Vincent, Hélène, Varga, Andreea, Martin Romano, Patricia, Vuagnat, Perrine, Besse, Benjamin, Planchard, David, Hollebecque, Antoine, Champiat, Stéphane, Marabelle, Aurélien, Michot, Jean-Marie, Massard, Christophe, Mezquita, Laura
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600023/ https://www.ncbi.nlm.nih.gov/pubmed/36291861 http://dx.doi.org/10.3390/cancers14205078

Ejemplares similares

Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types
por: Martin‐Romano, Patricia, et al.
Publicado: (2020)

Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potential
por: Baldini, Capucine, et al.
Publicado: (2019)

Case Report: Response to Immunotherapy, Can Radiotherapy Be a Troublemaker?
por: Martin-Romano, Patricia, et al.
Publicado: (2021)

Sustained cancer clinical trial activity in a French hospital during the first wave of the COVID-19 pandemic
por: Bayle, Arnaud, et al.
Publicado: (2021)

Association of the Lung Immune Prognostic Index with Immunotherapy Outcomes in Mismatch Repair Deficient Tumors
por: Auclin, Edouard, et al.
Publicado: (2021)

1617P Sustained cancer clinical trial activity during the COVID-19 pandemic
por: Bayle, A., et al.
Publicado: (2021)

Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers
por: Baldini, Capucine, et al.
Publicado: (2022)

Comment on Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176
por: Auclin, Edouard, et al.
Publicado: (2021)

Intratumoural administration and tumour tissue targeting of cancer immunotherapies
por: Melero, Ignacio, et al.
Publicado: (2021)

Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines?
por: Watson, Sarah, et al.
Publicado: (2018)

Prolonged Survival in a Patient with a Pancreatic Acinar Cell Carcinoma
por: Ploquin, Anne, et al.
Publicado: (2015)

Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers
por: Cabel, Luc, et al.
Publicado: (2018)

CD8(+)PD-1(+) to CD4(+)PD-1(+) ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers
por: Duchemann, Boris, et al.
Publicado: (2022)

The Lung Immune Prognostic Index (LIPI) stratifies prognostic groups in advanced non-small cell lung cancer (NSCLC) patients
por: Aldea, Mihaela, et al.
Publicado: (2020)

Integrin-α(V)-mediated activation of TGF-β regulates anti-tumour CD8 T cell immunity and response to PD-1 blockade
por: Malenica, Ines, et al.
Publicado: (2021)

Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer
por: Geraud, Arthur, et al.
Publicado: (2020)

A microsimulation model to assess the economic impact of immunotherapy in non-small cell lung cancer
por: Legoupil, Clémence, et al.
Publicado: (2020)

Atypical Listeria innocua strains possess an intact LIPI-3
por: Clayton, Evelyn M, et al.
Publicado: (2014)

LipiDisease: associate lipids to diseases using literature mining
por: More, Piyush, et al.
Publicado: (2021)

Predicting immunotherapy outcomes in patients with MSI tumors using NLR and CT global tumor volume
por: Belkouchi, Younes, et al.
Publicado: (2022)

Neurological complications induced by immune checkpoint inhibitors: a comprehensive descriptive case-series unravelling high risk of long-term sequelae
por: Plaçais, Léo, et al.
Publicado: (2021)

CD103(+)CD8(+) T(RM) Cells Accumulate in Tumors of Anti-PD-1-Responder Lung Cancer Patients and Are Tumor-Reactive Lymphocytes Enriched with Tc17
por: Corgnac, Stéphanie, et al.
Publicado: (2020)

Entomologic investigation of Plasmodium knowlesi vectors in Kuala Lipis, Pahang, Malaysia
por: Jiram, Adela I, et al.
Publicado: (2012)

Modulation of the Activity of Mycobacterium tuberculosis LipY by Its PE Domain
por: Garrett, Christopher K., et al.
Publicado: (2015)

LipiSensors: Exploiting Lipid Nanoemulsions to Fabricate Ionophore-Based Nanosensors
por: Dailey, Alexandra L., et al.
Publicado: (2020)

Synergizing liver systemic treatments with interventional oncology: friend or foe?
por: Jost, Raphaël, et al.
Publicado: (2022)

Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer
por: Park, Wungki, et al.
Publicado: (2019)

Trans-Resveratrol Oral Bioavailability in Humans Using LipiSperse™ Dispersion Technology
por: Briskey, David, et al.
Publicado: (2020)

Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockers
por: Nebot-Bral, Laetitia, et al.
Publicado: (2022)

Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancer
por: Duchemann, Boris, et al.
Publicado: (2021)

Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI)
por: De Giglio, Andrea, et al.
Publicado: (2020)

Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti–PD-1 + Antiangiogenesis in Malignant Pleural Mesothelioma
por: Danlos, François-Xavier, et al.
Publicado: (2023)

Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study
por: Manson, Guillaume, et al.
Publicado: (2019)

Clinical Trial of Thermal Pulsation (LipiFlow) in Meibomian Gland Dysfunction With Preteatment Meibography
por: Zhao, Yang, et al.
Publicado: (2016)

36‐month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer's disease
por: Soininen, Hilkka, et al.
Publicado: (2020)

Serology Identifies LIPyV as a Feline Rather than a Human Polyomavirus
por: Kamminga, Sergio, et al.
Publicado: (2023)

Biomarker Testing in Older Patients Treated for an Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer: The French ESME Real-Life Multicenter Cohort Experience
por: Lamy, Tina, et al.
Publicado: (2021)

Renal toxicities associated with pembrolizumab
por: Izzedine, Hassan, et al.
Publicado: (2018)

SARS-CoV-2 vaccines for cancer patients treated with immunotherapies: Recommendations from the French society for ImmunoTherapy of Cancer (FITC)
por: Gauci, Marie-Léa, et al.
Publicado: (2021)

Synergic prognostic value of 3D CT scan subcutaneous fat and muscle masses for immunotherapy-treated cancer
por: Decazes, Pierre, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a2ur8v02953l7tlkr0ehjg17um